参考文献/References:
[1].BetkierLipińska K, Ryczek R, Kwasiborski P, et al. Pulmonary arterial hypertension: modern diagnostics and therapy--Part 1[J]. Pol Merkur Lekarski,2013,34(204):355-359.
[2].Ghosh RK, Ball S, Das A, et al. Selexipag in pulmonary arterial hypertension: most updated evidence from recent preclinical and clinical studies[J]. J Clin Pharmacol, 2017,57(5):547-557.
[3].Noel ZR. Safety concerns regarding selexipag in pulmonary arterial hypertension[J]. AmJ Health S yst Pharm,2018,75(7):420.
[4].Li Q,Dimopoulos K,Zhang C,et al.Acute effect of inhaled iloprost in children with pulmonary arterial hypertension associated with simple congenital heart defects[J]. Pediatr Cardiol,2018,39(4):757-762.
[5]. Akagi S,Nakamura K,Matsubara H,et al. Epoprostenol therapy for pulmonary arterial hypertension[J]. Acta Med Okayama,2015,69(3):129-136.
[6]. Skoro-Sajer N,Gerges C,Balint OH,et al. Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension[J].Heart,2018,104(14):1195-1199.
[7]. Hill N S,Badesch D,Benza RL,et al. Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration[J]. Ann Am Thorac Soc,2015,12(2):269.
[8]. Kuang HY,Wu YH,Yi QJ,et al. The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease[J]. Medicine,2018,97(10):e0075.
[9]. 金沁纯,张晓春,管丽华,等. 基于单中心的波生坦治疗先天性心脏病相关肺动脉高压有效性及安全性分析[J]. 中国临床医学,2018,25(3):340-344.
[10]. Pulido T,Adzerikho I,Channick RN,et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension[J]. N Engl J Med,2013,369(9):809-818.
[11]. Gatzoulis MA, Landzberq M,Beqhetti M,et al. Evaluation of macitentan in patients with eisenmenger syndrome[J].Circulation,2019,139(1):51-63.
[12].Badesch DB,Feldman J,Keogh A,et al. ARIES-3:ambrisentan therapy in a diverse population of patients with pulmonary hypertension[J]. Cardiovasc Ther,2012,30(2):93-99.
[13].甘露,郭雨鑫,沈国军,等. 西地那非治疗高原地区先天性心脏病合并重度肺动脉高压的疗效观察[J]. 中国医药指南,2018,16(25):40.
[14]. Clavé MM,Maeda NY,Thomaz AM,et al. Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease[J]. Congenit Heart Dis,2019,14(2):246-255.
[15]. Reza Sabri M, Bigdelian H,Hosseinzadeh M,et al. Comparison of the therapeutic effects and side effects of tadalafil and sildenafil after surgery in young infants with pulmonary arterial hypertension due to systemic-to-pulmonary shunts[J]. Cardiol Young,2017,27(9):1686-1693.
[16].Xiao JW,Zhu XY,Wang QG,et al. Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects[J]. Circ J,2015,79(6):1342-1348.
[17].Stasch JP,Pacher P,Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease[J]. Circulation,2011,123(20):2263-2273.
[18].Simonneau G ,Rubin LJ,Galiè N ,et al. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension[J]. J Heart Lung Transplant,2014, 33(7):689-697.
[19].Coghlan JG, Channick R, Chin K, et al. Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study[J]. Am J Cardiovasc Drugs, 2018,18(1):37-47.
[20]. 中国医师学会心血管内科医师分会. 2015年先天性心脏病相关性肺动脉高压诊治中国专家共识[J]. 中国介入心脏病学杂志,2015,23(2):61-69.
[21].Huang ZW,Fan ZX,Sun JT,et al. The short- and medium-term results of transcatheter closure of atrial septal defect with severe pulmonary arterial hypertension[J]. Heart Vessels, 2012,27(6):603-609.
[22].Zhang DZ,Zhu XY,Lv B,et al. Trial occlusion to assess the risk of persistent pulmonary arterial hypertension after closure of a large patent ductus arteriosus in adolescents and adults with elevated pulmonary artery pressure[J]. Circ Cardiovasc Interv,2014,7(4):473-481.
[23].Sadiq M,Rehman AU,Hyder N,et al. Intermediate- and long-term follow-up of device closure of patent arterial duct with severe pulmonary hypertension:factors predicting outcome[J]. Cardiol Young,2017,27(1):26-36.
[24].Rajeshkumar R,Pavithran S,Sivakumar K,et al. Atrial septostomy with a predefined diameter using a novel occlutech atrial flow regulator improves symptoms and cardiac index in patients with severe pulmonary arterial hypertension[J]. Catheter Cardiovasc Interv, 2017,90(7):1145-1153.
[25].王志伟,郭建州,杨晓涵,等. 靶向降低肺动脉压药对先天性心脏病合并重度肺动脉高压的治疗价值[J]. 中国循环杂志,2016,31(z1):112-112.
[26]. 李勇新,许锁春,王海晨,等. 单向活瓣补片矫治先天性心脏病合并重度肺动脉高压伴双向分流的疗效评价[J]. 陕西医学杂志,2016,45(4):393-394.
[27].Hosseinpour A, Cullen S, Tsang V. Transplantation for adults with congenital heart disease[J]. Eur J Cardiothorac Surg ,2006,30(3):508-514.
[28].Goldfarb SB, Benden C, Edwards LB. The Registry of the International Society for Heart and Lung Transplantation Eighteenth Official Pediatric Lung and Heart-Lung Transplantation Report--2015; Focus Theme Early Graft Failure[J]. J Heart Lung Transplant,2015, 34(10):1264.
[29].Yusen RD,Edwards LB,Dipchand AI,et al. The Registry of the International Society for Heart and Lung Transplantation:Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme:Primary Diagnostic Indications for Transplant[J]. J Heart Lung Transplant,2016,35:1170-1184.
[30]. 田苗,张勇,陈寄梅. 成人先天性心脏病现状与未来[J]. 中国胸心血管外科临床杂志,2019,26(6):1-8.
相似文献/References:
[1]郭琳娟,洪葵.成人先天性心脏病心律失常的诊断和治疗进展[J].心血管病学进展,2015,(6):752.[doi:10.3969/j.issn.1004-3934.2015.06.024]
GUO Linjuan,HONG Kui.Advances in Diagnosis and Treatment of Adult Congenital Heart
Disease with Arrhythmia[J].Advances in Cardiovascular Diseases,2015,(6):752.[doi:10.3969/j.issn.1004-3934.2015.06.024]
[2]黄金秋 路发文 赵永康 陈宇雨 史红蕊 王萍 杨菊仙.先天性心脏病患儿营养状况及其危险因素分析[J].心血管病学进展,2020,(12):1324.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.023]
HUANG Jinqiu,LU Fawen,ZHAO Yongkang,et al.Nutritional Status in Children with Congenital Heart Disease and the Influential Factors[J].Advances in Cardiovascular Diseases,2020,(6):1324.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.023]
[3]周玲梅 张文倩 张智伟.体-肺动脉分流术在建立先天性心脏病动物模型中的应用进展[J].心血管病学进展,2021,(7):628.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.013]
ZHOU Lingmei,ZHANG Wenqian,ZHANG Zhiwei.Application Progress of Systemic Pulmonary Arterial Shunt in Animal Model of Congenital Heart Disease[J].Advances in Cardiovascular Diseases,2021,(6):628.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.013]
[4]林锡祥 杨菲菲 陈煦 何昆仑.人工智能赋能医学影像在先天性心脏病医学诊治中的研究进展[J].心血管病学进展,2022,(12):1063.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.002]
LIN Xixiang,YANG Feifei,CHEN Xu,et al.Artificial Intelligence Medical Imaging Technology in Medical Imaging of Congenital Heart Disease[J].Advances in Cardiovascular Diseases,2022,(6):1063.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.002]
[5]刘晓旭 莫绪明.先天性心脏病患儿心肺转流术后肠道损伤机制及治疗进展[J].心血管病学进展,2023,(6):501.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.0005]
LIU Xiaoxu,MO Xuming.Mechanism and Treatment of Intestinal Injury After Cardiopulmonary Bypass in Children with Congenital Heart Disease[J].Advances in Cardiovascular Diseases,2023,(6):501.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.0005]
[6]董捷 杜楚豪 董硕 刘顺 徐海涛 孙阳雪 邹孟轩 孙家树 李守军 杨克明 闫军.Uhl畸形诊断与治疗研究进展[J].心血管病学进展,2023,(8):686.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.004]
DONG Jie DU Chuhao DONG ShuoLIU Shun,XU HaitaoSUN YangxueZOU MengxuanSUN JiashuLI Shoujun,YANG Keming,et al.Diagnosis and Treatment for Uhls Anomaly[J].Advances in Cardiovascular Diseases,2023,(6):686.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.004]
[7]陈颖慧 冯奕源 冯炜琦 吴逸卓 鲁亚南 于昱.血管发育异常的先天性心脏病患儿中Vav2基因突变的筛查和功能分析[J].心血管病学进展,2023,(8):757.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.019]
CHEN Yinghui,FENG Yiyuan,FENG Weiqi,et al.Identification and Functional Analysis of Vav2 Novel Variant in Congenital Heart Diseases with Vascular Malformation[J].Advances in Cardiovascular Diseases,2023,(6):757.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.019]
[8]李强强 顾虹.中国儿童肺动脉高压诊治现状[J].心血管病学进展,2024,(1):7.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.003]
LI Qiangqiang,GU Hong.Current Status of Diagnosis and Treatment of Pulmonary Hypertension in Chinese Children[J].Advances in Cardiovascular Diseases,2024,(6):7.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.003]
[9]李思聪 罗勤 赵智慧 赵青 柳志红.房间隔缺损相关肺动脉高压机制及治疗进展[J].心血管病学进展,2024,(1):11.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.004]
LI Sicong,LUO Qin,ZHAO Zhihui,et al.Pathogenesis and Treatment of Pulmonary Hypertension Associated with Atrial Septal Defect[J].Advances in Cardiovascular Diseases,2024,(6):11.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.004]
[10]关璐茜 罗勤 胡海波.高原地区先天性心脏病相关性肺动脉高压的研究进展[J].心血管病学进展,2024,(1):15.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.005]
GUAN Luxi,LUO Qin,HU Haibo.Pulmonary Arterial Hypertension Associated with Congenital Heart Disease at High Altitude[J].Advances in Cardiovascular Diseases,2024,(6):15.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.005]